Forum for Science, Industry and Business
Sponsored by:     Siemens  n-tv 
Search our Site:

Topic (optional):

 

Home Reports Life Sciences Content

New version of tumor-suppressor linked to progression of childhood cancer

next article
19.10.2004

 


Researchers have discovered an unexpected role as a tumor promoter for a molecule that was previously thought to function exclusively as a cancer suppressor in neuroblastoma (NB), a highly aggressive and deadly childhood cancer. The study, published in the October issue of Cancer Cell, reveals new evidence about what stimulates progression of neuroblastoma and may provide a likely target for new anti-cancer therapies.


Neurotrophin tyrosine kinase receptor type I (TrkA) responds to nerve growth factor and plays a key role in the development of the nervous system. Mutated TrkA has been associated with many human cancers, including colon, thyroid and prostate cancers. However, previous studies have suggested that TrkA acts as a tumor-suppressor in NB. Dr. Andrew R. Mackay and colleagues from the University of L’Aquila in Italy found a previously undiscovered variant of TrkA, called TrkIII, which exhibits oncogenic properties in human NB cells. TrkIII levels are elevated in advanced stage NB tumors, suggesting that the molecule may play a role in cancer progression. The researchers found that the level of TrkIII resulting from altered splicing of TrkA transcripts is controlled in part by hypoxia, a condition where cells are deprived of oxygen that is known to contribute to cancer progression. The researchers found that TrkIII stimulated advancement of NB, in part, by interfering with the normal anti-oncogenic function of TrkA.

The researchers conclude that formation of TrkIII represents a tumor-promoting switch in NB. Preventing generation of TrkIII may serve to inhibit NB progression. "A potential mechanism for regulating NB progression based on alternative TrkAIII splicing rather than genetic TrkA abnormality would theoretically permit reversal by re-establishing regular TrkA (I/II) splicing, which would represent a potential therapeutic goal," explains Dr. Mackay.

Antonella Tacconelli, Antonietta R. Farina, Lucia Cappabianca, Giuseppina DeSantis, Alessandra Tessitore, Antonella Vetuschi,1 Roberta Sferra, Nadia Rucci, Beatrice Argenti, Isabella Screpanti, Alberto Gulino, and Andrew R. Mackay: "TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma"

Heidi Hardman | Source: EurekAlert!
Further information: www.cell.com

next article

More articles from Life Sciences:

nachricht New cancer target for non-Hodgkin's lymphoma
24.11.2009 | New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

nachricht New hydrogen-storage method discovered
24.11.2009 | Carnegie Institution

All articles from Life Sciences >>>

B2B Search

Product / Service
Company / Organisation

Latest News

Daycare may double TV time for young children

24.11.2009 | Studies and Analyses

Insomnia prevalent among cancer patients who receive chemotherapy

24.11.2009 | Studies and Analyses

How green is your house?

24.11.2009 | Social Sciences

VideoLinks

Event News

Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients

20.11.2009 | Event News

'Golden Age' for clinical psychology in Northern Ireland

20.11.2009 | Event News

New Perspectives in Marine Anti-Fouling Research

11.11.2009 | Event News